1646 8005



PATENT Attorney Docket No. LEX-009DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Lo et al.

SERIAL NO.:

09/977,034

GROUP NO.:

1646

FILING DATE:

October 11, 2001

EXAMINER:

D. Jiang

TITLE:

Methods of Treading a Condition by Administration of Fc-Interferon-

Alpha Fusion Protein

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of March, 2005.

Brenda L. MacLean

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page);
- 3. and a return receipt postcard.

OIPE							
TRANSMITTAL FORM			Application	Application Serial Number		09/977,034	
			Filing Date	Filing Date		October 11, 2001	
			First Named	First Named Inventor Lo		.0	
			Group Art U	Group Art Unit 164		646	
			Examiner N	Examiner Name		D. Jiang	
			Attorney Do	Attorney Docket No.		LEX-009DV	
			Confirmation	Confirmation No.		4315	
					+		
ENCLOSURES (check all that apply)							
	Fee Transmittal Form			e to File Missing		Notice of Appeal to Board of Patent Appeals and Interferences	
	☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)	
	Amendment/Response		Request For C Examination (Status Inquiry	
	☐ Preliminary ☐ After Final		Transmittal			Return Receipt Postcard	
	☐ Affidavits/declaration(s) ☐ Letter to Official Draftsperson	⊠		· ·	⊠	·	
	including Drawings [Total Sheets]		Terminal Disc			Certificate of Facsimile	
	Petition for Extension of Time			aration and Power r Utility or Design ttion		Transmission under 37 C.F.R. 1.8 Additional Enclosure(s) (please identify below)	
	Information Disclosure Statement		Small Entity S	tatement			
	Form PTO-1449 Copies of IDS Citations		CD(s) for large	e table or computer			
	Certified Copy of Priority Document(s)		Amendment A	fter Allowance			
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Certificate of Correction Certificate of Correction (in duplicate)				
CORRESPONDENCE ADDRESS				SIGNATURE BLO	OCK		
Direct all correspondence to: Patent Administrator Kirkpatrick & Lockhart Nicholson Graham LLP 75 State Street Boston, MA 02109-1808 Tel. No.: (617) 261-3100 Fax No.: (617) 261-3175				Date: March 8, 2005 Reg. No. 48,645 Tel. No.: (617) 261-3169 Fax No.: (617) 261-3175			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:

Lo et al.

ASSIGNEE:

EMD Lexigen Research Center Corp.

SERIAL NO.:

09/977,034

FILING DATE:

October 11, 2001

TITLE:

Methods of Treading a Condition by Administration of Fc-Interferon-Alpha Fusion

Protein

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the above-identified patent application, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 022832** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent application to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent application is EMD Lexigen Research Center Corp., by virtue of the chain of title from the inventors of the above-identified patent application to the current assignee, as shown below:

By assignment on September 11, 2000, from inventors Kin-Ming Lo, Yaping Sun, and Stephen D. Gillies to Lexigen Pharmaceuticals Corp., recorded in the U.S. Patent and Trademark Office on November 5, 2003, at Reel No. 014656, Frame No. 0444; and

By change of corporate name from Lexigen Pharmaceuticals Corp. to EMD Lexigen Research Center Corp., on May 30, 2002, recorded in the U.S. Patent and Trademark Office on December 19, 2003, at Reel No. 014815, Frame No. 0751.

Respectfully submitted,

Dated: 3/3/2005

Stephen D. Gillies, Ph.D.

President

EMD Lexigen Research Center Corp.

Bedford Campus

45A Middlesex Turnpike

Billerica, MA 01821